Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

June 5, 2018

Primary Completion Date

December 15, 2023

Study Completion Date

December 15, 2023

Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG

JCAR017

Specified dose on specified days

Trial Locations (20)

1090

Local Institution - 101, Vienna

3010

Local Institution - 251, Bern

9000

Local Institution - 351, Ghent

10126

Local Institution - 401, Torino

20133

Local Institution - 402, Milan

50937

Local Institution - 151, Cologne

59037

Local Institution - 202, Lille

69120

Local Institution - 155, Heidelberg

69495

Local Institution - 201, Pierre-Bénite

75475

Local Institution - 203, Paris

81377

Local Institution - 154, München

89081

Local Institution - 153, Ulm

00029

Local Institution - 551, Helsinki

01307

Local Institution - 152, Dresden

104-0045

Local Institution - 601, Chuo-ku

105-8470

Local Institution - 602, Minato-ku

3015 CE

Local Institution - 301, Rotterdam

08035

Local Institution - 451, Barcelona

M20 4BX

Local Institution - 502, Manchester

WC1E 6BT

Local Institution - 501, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY